Skip to content
mapperlab
← Dashboard
Stock

MYGN

MYRIAD GENETICS INC
Latest close $4.308 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
8
27 funds tracked
Ever held
11
Current + past
New this quarter
0
Exited this quarter
0

Marquee-fund ownership over time

Feb 14, 2014Aug 14, 2015Nov 14, 2019May 15, 2025
Now
8

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Glenview Capital$25$4.30-82%
Citadel Advisors$28$4.30-84%
D.E. Shaw$28$4.30-84%
AQR Capital Management$28$4.30-84%
Millennium Management$28$4.30-84%
Point72 Asset Management$28$4.30-84%
Renaissance Technologies$16$4.30-73%
Two Sigma Investments$4.11$4.30+5%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Maverick Capital→ $22+4%
Tiger Global→ $33+5%
Viking Global Investors→ $33-9%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at MYRIAD GENETICS INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
11
Filings · last 90d
25
Total on file
604
Recent SEC buffer
Most recent
Jun 9, 2026

30d / 90d windows measured from Jun 9, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 604 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · MYRIAD GENETICS INC

Annual figures sourced directly from MYRIAD GENETICS INC's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$824.5M
FY2025-2% YoY
Net income
-$365.9M
FY2025-187% YoY
EPS (diluted)
$-3.95
FY2025-180% YoY
Free cash flow(?)
$1.8M
FY2025+121% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for MYRIAD GENETICS INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Two Sigma InvestmentsQ2 2025open$4.11$3.65-11%
Renaissance TechnologiesQ4 2024open$16$3.65-77%
Citadel AdvisorsQ3 2024open$28$3.65-87%
D.E. ShawQ3 2024open$28$3.65-87%
AQR Capital ManagementQ3 2024open$28$3.65-87%
Millennium ManagementQ3 2024open$28$3.65-87%
Point72 Asset ManagementQ3 2024open$28$3.65-87%
Glenview CapitalQ4 2019open$25$3.65-85%
Maverick CapitalQ3 2016Q2 2017$21$22+4%
Viking Global InvestorsQ3 2014Q4 2014$36$33-9%
Tiger GlobalQ1 2014Q3 2015$31$33+5%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.